Untitled document
Determination—Conditions (PB 119 of 2008)
made under paragraph 98C(1)(b) of the
National Health Act 1953
Compilation No. 72
Compilation date: 1 December 2016
Includes amendments up to: PB 108 of 2016
Registered: 2 December 2016
About this compilation
This compilation
This is a compilation of the Determination—Conditions (PB 119 of 2008) that shows the text of the law as amended and in force on 1 December 2016 (the compilation date).
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register ( The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Editorial changes
For more information about any editorial changes made in this compilation, see the endnotes.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.
Self-repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
Determination–Conditions (PB 119 of 2008)
Definitions
3. “Act” means the National Health Act 1953;
“approved ex‑manufacturer price” has the same meaning as in subsection 84(1) of the Act;
“Commonwealth price” has the same meaning as in subsection 84(1) of the Act;
“extemporaneously‑prepared pharmaceutical benefit” means a pharmaceutical benefit other than a ready‑prepared pharmaceutical benefit;
“pack quantity” has the same meaning as in subsection 84(1) of the Act;
“prescription” includes a prescription written on an authority prescription made under regulation 13 of the Regulations, a prescription required to be submitted to the Chief Executive Medicare for the purposes of a determination made under subsection 85(2A) or subsection 85A(2) of the Act, a repeat authorisation, or a deferred supply authorisation;
“proportional ex‑manufacturer price” has the same meaning as in subsection 84(1) of the Act;
“ready‑prepared pharmaceutical benefit” means a listed brand of a pharmaceutical item;
“Regulations” means the National Health (Pharmaceutical Benefits) Regulations 1960 made under the Act;
“standard formula preparation” means an extemporaneously‑prepared pharmaceutical benefit that is listed in Schedule 5 to this Determination.
Schedules
4. For the supply of pharmaceutical benefits:
(a) pharmaceutical benefits that involve the admixture of ready‑prepared ingredients are set out in Schedule 1;
(b) drugs that are used in the preparation of extemporaneously‑prepared pharmaceutical benefits and that are unstable or packed sterile and unused quantities of which are unsuitable for future use are set out in Schedule 2;
(c) pharmaceutical benefits that are classified as dangerous drugs for the purpose of payment of a dangerous drug fee are pharmaceutical benefits that have the pharmaceutical items which have the listed drug in the form set out in Schedule 3 to this Determination;
(d) pharmaceutical benefits the complete pack of which shall be supplied regardless of any lesser quantity ordered are pharmaceutical benefits that have the pharmaceutical items which have the listed drug in the form set out in Schedule 4.
Brand identified
. Where a prescription identifies the ready‑prepared pharmaceutical benefit to be supplied by reference to a particular brand, the amount payable shall be based on the approved ex‑manufacturer price or proportional ex‑manufacturer price for a pack quantity of that brand.
Brand not identified
. Where a prescription does not identify the ready‑prepared pharmaceutical benefit to be supplied by reference to a particular brand, the amount payable shall be based on the approved ex‑manufacturer price or proportional ex‑manufacturer price for a pack quantity of the brand of that benefit, being a brand which is available from a wholesale source in the capital city of the State in which the benefit is supplied, for which the Commonwealth price for the supply of the benefit is lowest.
Packs
. Where a prescription calls for a quantity of one of the pharmaceutical benefits that have the pharmaceutical items which have the form of the listed drug set out in Schedule 4 that is less than the quantity contained in the size of unit included in the particulars specified in the column headed 'Form' in that Schedule in relation to that benefit, the complete pack shall be supplied.
Variation of medicinal preparation
. A medicinal preparation that is a variation of a standard formula preparation, due to the addition or deletion of an ingredient or to variation of the dose, or that is a combination of standard formula preparations, shall be deemed not to be a standard formula preparation.
Election—extemporaneously-prepared pharmaceutical benefits
. An election made pursuant to section 31 of the determination made under paragraph 98B(1)(a) of the Act shall be made in writing to the Chief Executive Medicare and shall remain in force for a period of not less than 3 months from and including the date of election, but may be revoked in writing at any time after the expiration of that period; and while the election remains in force, the amount payable to the approved pharmacist or approved medical practitioner, in respect of the supply of an extemporaneously‑prepared pharmaceutical benefit that is not a standard formula preparation, shall be the amount calculated in accordance with section 18 of the determination made under paragraph 98B(1)(a) of the Act.
| SCHEDULE 1—PHARMACEUTICAL BENEFITS THAT INVOLVE THE ADMIXTURE OF READY‑PREPARED INGREDIENTS | |
| Listed Drug | Form (strength, type, size, etc.) |
| Amoxycillin with Water – Purified BP | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL |
| Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL | |
| Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL | |
| Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL | |
| Amoxycillin with Clavulanic Acid and Water – Purified BP | Powder for oral suspension containing 125 mg amoxycillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL Powder for oral suspension containing 400 mg amoxycillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL |
| Azithromycin with Water – Purified BP | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL |
| Cefaclor with Water – Purified BP | Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL |
| Cefuroxime with Water ─ Purified BP | Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL |
| Cephalexin with Water – Purified BP | Granules for oral suspension 125 mg per 5 mL, 100 mL Granules for oral suspension 250 mg per 5 mL, 100 mL |
| Clarithromycin with Water – Purified BP | Powder for oral liquid 250 mg per 5 mL, 50 mL |
| Erythromycin with Water – Purified BP | Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL Powder for oral liquid 400 mg (as ethyl succinate) per 5 mL, 100 mL |
| Flucloxacillin with Water – Purified BP | Powder for oral liquid 125 mg (as sodium) per 5 mL, 100 mL Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL |
| Fluconazole with Water – Purified BP | Powder for oral suspension 50 mg in 5 mL, 35 mL |
| Mycophenolic Acid with Water – Purified BP | Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL |
| Phenoxymethylpenicillin with Water – Purified BP | Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL |
| Valganciclovir | Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL |
| Voriconazole with Water—Purified BP | Powder for oral suspension 40 mg per mL, 70 mL |
| SCHEDULE 2—DRUGS THAT ARE USED IN THE PREPARATION OF EXTEMPORANEOUSLY‑PREPARED PHARMACEUTICAL BENEFITS AND THAT ARE UNSTABLE OR PACKED STERILE AND UNUSED QUANTITIES OF WHICH ARE UNSUITABLE FOR FUTURE USE | |
| Listed Drug | Form (strength, type, size, etc.) |
| Water For Injections—sterilised BP | |
| SCHEDULE 3—PHARMACEUTICAL BENEFITS THAT ARE CLASSIFIED AS DANGEROUS DRUGS FOR THE PURPOSE OF PAYMENT OF A DANGEROUS DRUG FEE | |
| Listed Drug | Form (strength, type, size, etc.) |
| Alprazolam | Tablet 250 micrograms |
| Tablet 500 micrograms | |
| Tablet 1 mg | |
| Tablet 2 mg | |
| Buprenorphine | Transdermal patch 5 mg |
| Transdermal patch 10 mg | |
| Transdermal patch 15 mg | |
| Transdermal patch 20 mg | |
| Transdermal patch 25 mg | |
| Transdermal patch 30 mg | |
| Transdermal patch 40 mg | |
| Codeine | Tablet containing codeine phosphate 30 mg |
| Dexamphetamine | Tablet containing dexamphetamine sulfate 5 mg |
| Fentanyl | Lozenge 200 micrograms (as citrate) |
| Lozenge 400 micrograms (as citrate) | |
| Lozenge 600 micrograms (as citrate) | |
| Lozenge 800 micrograms (as citrate) | |
| Lozenge 1200 micrograms (as citrate) | |
| Lozenge 1600 micrograms (as citrate) | |
| Tablet (orally disintegrating) 100 micrograms (as citrate) | |
| Tablet (orally disintegrating) 200 micrograms (as citrate) | |
| Tablet (orally disintegrating) 400 micrograms (as citrate) | |
| Tablet (orally disintegrating) 600 micrograms (as citrate) | |
| Tablet (orally disintegrating) 800 micrograms (as citrate) | |
| Tablet (sublingual) 100 micrograms (as citrate) | |
| Tablet (sublingual) 200 micrograms (as citrate) | |
| Tablet (sublingual) 300 micrograms (as citrate) | |
| Tablet (sublingual) 400 micrograms (as citrate) | |
| Tablet (sublingual) 600 micrograms (as citrate) | |
| Tablet (sublingual) 800 micrograms (as citrate) | |
| Transdermal patch 1.28 mg | |
| Transdermal patch 2.063 mg | |
| Transdermal patch 2.1 mg | |
| Transdermal patch 2.55 mg | |
| Transdermal patch 4.125 mg | |
| Transdermal patch 4.2 mg | |
| Transdermal patch 5.10 mg | |
| Transdermal patch 7.65 mg | |
| Transdermal patch 8.25 mg | |
| Transdermal patch 8.4 mg | |
| Transdermal patch 10.20 mg | |
| Transdermal patch 12.375 mg | |
| Transdermal patch 12.6 mg | |
| Transdermal patch 16.5 mg | |
| Transdermal patch 16.8 mg | |
| Hydromorphone | Tablet containing hydromorphone hydrochloride 2 mg |
| Tablet containing hydromorphone hydrochloride 4 mg | |
| Tablet containing hydromorphone hydrochloride 8 mg | |
| Tablet (modified release) containing hydromorphone hydrochloride 4 mg | |
| Tablet (modified release) containing hydromorphone hydrochloride 8 mg | |
| Tablet (modified release) containing hydromorphone hydrochloride 16 mg | |
| Tablet (modified release) containing hydromorphone hydrochloride 32 mg | |
| Tablet (modified release) containing hydromorphone hydrochloride 64 mg | |
| Oral liquid containing hydromorphone hydrochloride 1 mg per mL, 473 mL | |
| Injection containing hydromorphone hydrochloride 2 mg in 1 mL | |
| Injection containing hydromorphone hydrochloride 10 mg in 1 mL | |
| Injection containing hydromorphone hydrochloride 50 mg in 5 mL | |
| Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 30 mg |
| Capsule containing lisdexamfetamine dimesilate 50 mg | |
| Capsule containing lisdexamfetamine dimesilate 70 mg | |
| Methadone | Tablet containing methadone hydrochloride 10 mg |
| Oral liquid containing methadone hydrochloride 25 mg per 5 mL, 200 mL | |
| Injection containing methadone hydrochloride 10 mg in 1 mL | |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 10 mg |
| Tablet containing methylphenidate hydrochloride 18 mg (extended release) | |
| Tablet containing methylphenidate hydrochloride 27 mg (extended release) | |
| Tablet containing methylphenidate hydrochloride 36 mg (extended release) | |
| Tablet containing methylphenidate hydrochloride 54 mg (extended release) | |
| Capsule containing methylphenidate hydrochloride 20 mg (modified release) | |
| Capsule containing methylphenidate hydrochloride 30 mg (modified release) | |
| Capsule containing methylphenidate hydrochloride 40 mg (modified release) | |
| Morphine | Tablet containing morphine sulfate 10 mg |
| Tablet containing morphine sulfate 20 mg | |
| Tablet containing morphine sulfate 30 mg | |
| Tablet containing morphine sulfate 5 mg (controlled release) | |
| Tablet containing morphine sulfate 10 mg (controlled release) | |
| Tablet containing morphine sulfate 15 mg (controlled release) | |
| Tablet containing morphine sulfate 30 mg (controlled release) | |
| Tablet containing morphine sulfate 60 mg (controlled release) | |
| Tablet containing morphine sulfate 100 mg (controlled release) | |
| Tablet containing morphine sulfate 200 mg (controlled release) | |
| Capsule containing morphine sulfate 10 mg (containing sustained release pellets) | |
| Capsule containing morphine sulfate 20 mg (containing sustained release pellets) | |
| Capsule containing morphine sulfate 30 mg (controlled release) | |
| Capsule containing morphine sulfate 50 mg (containing sustained release pellets) | |
| Capsule containing morphine sulfate 60 mg (controlled release) | |
| Capsule containing morphine sulfate 90 mg (controlled release) | |
| Capsule containing morphine sulfate 100 mg (containing sustained release pellets) | |
| Capsule containing morphine sulfate 120 mg (controlled release) | |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate 20 mg per sachet | |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate 30 mg per sachet | |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate 60 mg per sachet | |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate 100 mg per sachet | |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate 200 mg per sachet | |
| Oral solution containing morphine hydrochloride 2 mg per mL, 200 mL | |
| Oral solution containing morphine hydrochloride 5 mg per mL, 200 mL | |
| Oral solution containing morphine hydrochloride 10 mg per mL, 200 mL | |
| Injection containing morphine hydrochloride 10 mg in 1 mL | |
| Injection containing morphine hydrochloride 20 mg in 1 mL | |
| Injection containing morphine hydrochloride 50 mg in 5 mL | |
| Injection containing morphine hydrochloride 100 mg in 5 mL | |
| Injection containing morphine sulfate 10 mg in 1 mL | |
| Injection containing morphine tartrate 120 mg in 1.5 mL | |
| Injection containing morphine sulfate 15 mg in 1 mL | |
| Injection containing morphine sulfate 30 mg in 1 mL | |
| Oxycodone | Tablet containing oxycodone hydrochloride 5 mg |
| Capsule containing oxycodone hydrochloride 5 mg | |
| Capsule containing oxycodone hydrochloride 10 mg | |
| Capsule containing oxycodone hydrochloride 20 mg | |
| Oral solution containing oxycodone hydrochloride 5 mg per 5 mL, 250 mL | |
| Tablet containing oxycodone hydrochloride 10 mg (controlled release) | |
| Tablet containing oxycodone hydrochloride 15 mg (controlled release) | |
| Tablet containing oxycodone hydrochloride 20 mg (controlled release) | |
| Tablet containing oxycodone hydrochloride 30 mg (controlled release) | |
| Tablet containing oxycodone hydrochloride 40 mg (controlled release) | |
| Tablet containing oxycodone hydrochloride 80 mg (controlled release) | |
| Suppository 30 mg (as pectinate) | |
| Oxycodone with naloxone | Tablet (controlled release) containing oxycodone hydrochloride 2.5 mg with naloxone hydrochloride 1.25 mg |
| Tablet (controlled release) containing oxycodone hydrochloride 5 mg with naloxone hydrochloride 2.5 mg | |
| Tablet (controlled release) containing oxycodone hydrochloride 10 mg with naloxone hydrochloride 5 mg | |
| Tablet (controlled release) containing oxycodone hydrochloride 15 mg with naloxone hydrochloride 7.5 mg | |
| Tablet (controlled release) containing oxycodone hydrochloride 20 mg with naloxone hydrochloride 10 mg | |
| Tablet (controlled release) containing oxycodone hydrochloride 30 mg with naloxone hydrochloride 15 mg | |
| Tablet (controlled release) containing oxycodone hydrochloride 40 mg with naloxone hydrochloride 20 mg | |
| Tapentadol | Tablet (modified release) 50 mg (as hydrochloride) |
| Tablet (modified release) 100 mg (as hydrochloride) | |
| Tablet (modified release) 150 mg (as hydrochloride) | |
| Tablet (modified release) 200 mg (as hydrochloride) | |
| Tablet (modified release) 250 mg (as hydrochloride) | |
| SCHEDULE 4—PHARMACEUTICAL BENEFITS THE COMPLETE PACK OF WHICH SHALL BE SUPPLIED REGARDLESS OF ANY LESSER QUANTITY ORDERED | |
| Listed Drug | Form (strength, type, size, etc.) |
| Aciclovir | Eye ointment 30 mg per g, 4.5 g |
| Aclidinium | Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses |
| Aclidinium with eformoterol | Powder for oral inhalation in breath actuated device containing aclidinium 340 micrograms (as bromide) with eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses |
| Adapalene with benzoyl peroxide | Gel 1 mg‑25 mg per g, 30 g |
| Alendronic acid with colecalciferol and calcium | Pack containing 4 tablets containing alendronic acid 70 mg (as alendronate sodium) with 140 micrograms colecalciferol and 48 tablets calcium 500 mg (as carbonate) |
| Amino acid formula with fat, carbohydrate, without phenylalanine | Tablet: modified release, 70.8 g protein per 100 g, 110 g (PKU Easy Microtabs) |
| Amoxycillin | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL |
| Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL | |
| Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL | |
| Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL | |
| Amoxycillin with Clavulanic Acid | Powder for oral suspension containing 125 mg amoxycillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL Powder for oral suspension containing 400 mg amoxycillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL |
| Apraclonidine | Eye drops 5 mg (as hydrochloride) per mL, 10 mL |
| Atenolol | Oral solution 50 mg in 10 mL, 300 mL |
| Atovaquone | Oral suspension 750 mg per 5 mL, 210 mL |
| Atropine | Eye drops containing atropine sulfate 10 mg per mL, 15 mL |
| Azithromycin | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL |
| Beclomethasone | Pressurised inhalation containing beclomethasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation) |
| Pressurised inhalation containing beclomethasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation) | |
| Pressurised inhalation in breath actuated device containing beclomethasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation) | |
| Pressurised inhalation in breath actuated device containing beclomethasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation) | |
| Benzydamine | Mouth and throat rinse containing benzydamine hydrochloride 22.5 mg per 15 mL, 500 mL |
| Betaine | Oral powder 180 g |
| Betaxolol | Eye drops, suspension, 2.5 mg (as hydrochloride) per mL, 5 mL Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL |
| Bimatoprost | Eye drops 300 micrograms per mL, 3 mL |
| Eye drops 300 micrograms per mL, single dose units 0.4 mL, 30 | |
| Bimatoprost with timolol | Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL |
| Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, single dose units 0.4 mL, 30 | |
| Bisacodyl | Enemas 10 mg in 5 mL, 25 |
| Brimonidine | Eye drops containing brimonidine tartrate 1.5 mg per mL, 5 mL |
| Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL | |
| Brimonidine with Timolol | Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg (as maleate) per mL, 5 mL |
| Brinzolamide | Eye drops 10 mg per mL, 5 mL |
| Brinzolamide with brimonidine | Eye drops 10 mg brinzolamide and 2 mg brimonidine tartarate per mL, 5 mL |
| Brinzolamide with Timolol | Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL |
| Budesonide | Nebuliser suspension 500 micrograms in 2 mL single dose units, 30 |
| Nebuliser suspension 1 mg in 2 mL single dose units, 30 | |
| Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses | |
| Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 oses | |
| Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses | |
| Budesonide with Eformoterol | Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses |
| Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses, 2 | |
| Calcipotriol with betamethasone | Gel containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g |
| Gel containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g | |
| Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g | |
| Captopril | Oral solution 5 mg per mL, 95 mL |
| Carbamazepine | Oral suspension 100 mg per 5 mL, 300 mL |
| Carbomer | Eye gel 2 mg per g, 10 g |
| Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 15 mL |
| Eye drops containing carmellose sodium 10 mg per mL, 15 mL | |
| Carmellose with glycerin | Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL |
| Carmustine | Implants 7.7 mg, 8 |
| Cefaclor | Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL |
| Cefuroxime | Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL |
| Cephalexin | Granules for oral suspension 125 mg per 5 mL, 100 mL Granules for oral suspension 250 mg per 5 mL, 100 mL |
| Chlorpromazine | Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL |
| Ciclesonide | Pressurised inhalation 80 micrograms per dose, 120 doses (CFC‑free formulation) Pressurised inhalation 160 micrograms per dose, 120 doses (CFC‑free formulation) |
| Ciprofloxacin | Ear drops 3 mg (as hydrochloride) per mL, 5 mL |
| Citrulline | Tablet 1 g, 300 (Citrulline Easy) |
| Clarithromycin | Powder for oral liquid 250 mg per 5 mL, 50 mL |
| Clobetasol | Shampoo containing clobetasol propionate 500 micrograms per mL, 125 mL |
| Clonazepam | Oral liquid 2.5 mg per mL, 10 mL |
| Coal tar | Foam 20 mg per g, 100 g |
| Coal Tar ‑ Prepared | Gel 10 mg per g, 100 mL |
| Colestipol | Oral powder, sachets containing colestipol hydrochloride 5 g, 120 |
| Cromoglycic Acid | Pressurised inhalation containing sodium cromoglycate 1 mg per dose, 200 doses (CFC‑free formulation) |
| Pressurised inhalation containing sodium cromoglycate 5 mg per dose, 112 doses (CFC‑free formulation) | |
| Eye drops containing sodium cromoglycate 20 mg per mL, 10 mL | |
| Degarelix | Powder for injection 120 mg (as acetate), 2, injection set |
| Desmopressin | Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 60 actuations, 6 mL |
| Dexamethasone | Eye drops 1 mg per mL, 5 mL |
| Dexamethasone with Framycetin and Gramicidin Diazepam | Ear drops containing dexamethasone 500 micrograms (as sodium metasulfobenzoate), framycetin sulfate 5 mg and gramicidin 50 micrograms per mL, 8 mL Oral liquid 1 mg in 1 mL, 100 mL |
| Dorzolamide | Eye drops 20 mg (as hydrochloride) per mL, 5 mL |
| Dorzolamide with Timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL |
| Eformoterol | Powder for oral inhalation in breath actuated device containing eformoterol fumarate dihydrate 6 micrograms per dose, 60 doses Powder for oral inhalation in breath actuated device containing eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses |
| Electrolyte Replacement, Oral | Oral rehydration salts containing glucose 3.56 g, sodium chloride 470 mg, potassium chloride 300 mg and sodium acid citrate 530 mg per sachet, 10 |
| Erythromycin | Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL Powder for oral liquid 400 mg (as ethyl succinate) per 5 mL, 100 mL |
| Escitalopram | Oral solution 20 mg (as oxalate) per mL, 15 mL |
| Esomeprazole and Clarithromycin and Amoxycillin | Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium), 14 tablets clarithromycin 500 mg and 28 capsules amoxycillin 500 mg (as trihydrate) |
| Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxycillin 500 mg (as trihydrate) | |
| Ethosuximide | Oral solution 250 mg per 5 mL, 200 mL |
| Ezetimibe and rosuvastatin | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) |
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) | |
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) | |
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) | |
| Ferrous Sulfate | Oral liquid 30 mg per mL, 250 mL |
| Flucloxacillin | Powder for oral liquid 125 mg (as sodium) per 5 mL, 100 mL Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL |
| Fluorometholone | Eye drops 1 mg per mL, 5 mL Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL |
| Fluticasone | Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC‑free formulation) |
| Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC‑free formulation) | |
| Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC‑free formulation) | |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses | |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses | |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms per dose, 60 doses | |
| Fluticasone with eformoterol | Pressurised inhalation containing fluticasone propionate 50 micrograms with eformoterol fumarate dihydrate 5 micrograms per dose, 120 doses |
| Pressurised inhalation containing fluticasone propionate 125 micrograms with eformoterol fumarate dihydrate 5 micrograms per dose, 120 doses | |
| Pressurised inhalation containing fluticasone propionate 250 micrograms with eformoterol fumarate dihydrate 10 micrograms per dose, 120 doses | |
| Fluticasone with Salmeterol | Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) |
| Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | |
| Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | |
| Fluticasone with vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses |
| Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | |
| Framycetin | Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL |
| Frusemide | Oral solution 10 mg per mL, 30 mL |
| Gentamicin | Eye drops 3 mg (as sulfate) per mL, 5 mL |
| Glyceryl Trinitrate | Tablets 600 micrograms, 100 Sublingual spray (pump pack) 400 micrograms per dose, 200 doses |
| Goserelin and Bicalutamide | Pack containing 1 subcutaneous implant containing goserelin 3.6 mg (as acetate) in pre‑filled injection syringe and 28 tablets bicalutamide 50 mg Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre‑filled injection syringe and 28 tablets bicalutamide 50 mg Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre‑filled injection syringe and 84 tablets bicalutamide 50 mg |
| Haloperidol | Oral solution 2 mg per mL, 100 mL |
| Hyaluronic acid | Eye drops containing sodium hyaluronate 1 mg per mL, 10 mL |
| Eye drops containing sodium hyaluronate 2 mg per mL, 10 mL | |
| Hydrocortisone | Eye ointment containing hydrocortisone acetate 10 mg per g, 5 g |
| Cream containing hydrocortisone acetate 10 mg per g, 50 g | |
| Ointment containing hydrocortisone acetate 10 mg per g, 50 g | |
| Hypromellose | Eye drops 3 mg per mL, 15 mL Eye drops 5 mg per mL, 15 mL |
| Hypromellose with Carbomer 980 | Ocular lubricating gel 3 mg‑2 mg per g, 10 g |
| Hypromellose with Dextran | Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL |
| Ketoconazole | Cream 20 mg per g, 30 g Shampoo 10 mg per g, 100 mL Shampoo 20 mg per g, 60 mL |
| Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL |
| Latanoprost with Timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL |
| Leuprorelin | I.M. injection (3 month modified release), powder for injection containing leuprorelin acetate 30 mg with diluent in pre-filled dual-chamber syringe |
| Leuprorelin and bicalutamide | Pack containing 1 syringe containing leuprorelin 7.5 mg (as acetate) and 28 tablets bicalutamide 50 mg |
| Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 28 tablets bicalutamide 50 mg | |
| Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 84 tablets bicalutamide 50 mg | |
| Levetiracetam | Oral solution 100 mg per mL, 300 mL |
| Macrogol 3350 | Powder for oral solution 510 g |
| Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | |
| Sachets containing powder for oral solution 17 g, 30 | |
| Mercaptopurine | Oral suspension 20 mg per mL, 100 mL |
| Metronidazole | Oral suspension containing metronidazole benzoate 320 mg per 5 mL, 100 mL Suppositories 500 mg, 10 |
| Miconazole | Cream containing miconazole nitrate 20 mg per g, 30 g |
| Cream containing miconazole nitrate 20 mg per g, 70 g | |
| Powder containing miconazole nitrate 20 mg per g, 30 g | |
| Tincture 20 mg per mL, 30 mL | |
| Mifepristone and misoprostol | Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms |
| Mupirocin | Nasal ointment 20 mg (as calcium) per g, 3 g |
| Mycophenolic Acid | Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL |
| Nafarelin | Nasal spray (pump pack) 200 micrograms (as acetate) per dose, 60 doses |
| Naproxen | Oral suspension 125 mg per 5 mL, 474 mL |
| Nedocromil | Pressurised inhalation containing nedocromil sodium 2 mg per dose, 112 doses (CFC‑free formulation) |
| Netupitant with Palonosetron | Capsule containing netupitant 300 mg with palonosetron 500 microgram (as hydrochloride) |
| Nicorandil | Tablets 10 mg, 60 Tablets 20 mg, 60 |
| Oestradiol | Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28 |
| Transdermal patches 390 micrograms, 8 | |
| Transdermal patches 750 micrograms (as hemihydrate), 8 | |
| Transdermal patches 2 mg, 4 | |
| Transdermal patches 585 micrograms, 8 | |
| Transdermal patches 1.5 mg (as hemihydrate), 8 | |
| Transdermal patches 3.8 mg, 4 | |
| Transdermal patches 780 micrograms, 8 | |
| Transdermal patches 5.7 mg, 4 | |
| Transdermal patches 1.17 mg, 8 | |
| Transdermal patches 3 mg (as hemihydrate), 8 | |
| Transdermal patches 7.6 mg, 4 | |
| Transdermal patches 1.56 mg, 8 | |
| Oestradiol and Oestradiol with Dydrogesterone | Pack containing 14 tablets oestradiol 1 mg and 14 tablets oestradiol 1 mg with dydrogesterone 10 mg |
| Pack containing 14 tablets oestradiol 2 mg and 14 tablets oestradiol 2 mg with dydrogesterone 10 mg | |
| Oestradiol and Oestradiol with Norethisterone | Pack containing 4 transdermal patches 780 micrograms oestradiol (as hemihydrate) and 4 transdermal patches 620 micrograms oestradiol (as hemihydrate) with 2.7 mg norethisterone acetate |
| Pack containing 4 transdermal patches 780 micrograms oestradiol (as hemihydrate) and 4 transdermal patches 510 micrograms oestradiol (as hemihydrate) with 4.8 mg norethisterone acetate | |
| Oestradiol with Norethisterone | Transdermal patches containing 620 micrograms oestradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 |
| Transdermal patches containing 510 micrograms oestradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 | |
| Oestriol | Pessaries 500 micrograms, 15 Vaginal cream 1 mg per g, 15 g |
| Ondansetron | Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL |
| Oxybutynin | Transdermal patches 36 mg, 8 |
| Paracetamol | Oral liquid 120 mg per 5 mL, 100 mL Oral liquid 240 mg per 5 mL, 200 mL |
| Paraffin | Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g |
| Peginterferon beta-1a | Pack containing single use injection pens containing 63 micrograms in 0.5 mL and 94 micrograms in 0.5 mL |
| Permethrin | Cream 50 mg per g, 30 g |
| Phenytoin | Oral suspension 30 mg per 5 mL, 500 mL |
| Pilocarpine | Eye drops containing pilocarpine hydrochloride 10 mg per mL, 15 mL |
| Eye drops containing pilocarpine hydrochloride 20 mg per mL, 15 mL | |
| Eye drops containing pilocarpine hydrochloride 40 mg per mL, 15 mL | |
| Pimecrolimus | Cream 10 mg per g, 15 g |
| Polyethylene Glycol 400 with Propylene Glycol | Eye drops 4 mg‑3 mg per mL, 15 mL |
| Polyvinyl Alcohol | Eye drops 14 mg per mL, 15 mL |
| Eye drops 14 mg per mL, 15 mL (contains sodium chlorite/hydrogen peroxide as preservative) | |
| Eye drops 30 mg per mL, 15 mL (contains sodium chlorite/hydrogen peroxide as preservative) | |
| Prednisolone | Oral solution 5 mg (as sodium phosphate) per mL, 30 mL |
| Prednisolone with Phenylephrine | Eye drops containing prednisolone acetate 10 mg with phenylephrine hydrochloride 1.2 mg per mL, 10 mL |
| Quinagolide | Pack containing 3 tablets quinagolide 25 micrograms (as hydrochloride) and 3 tablets quinagolide 50 micrograms (as hydrochloride) |
| Reteplase | Pack containing 2 vials powder for injection 10 units, 2 single use pre‑filled syringes with solvent, 2 reconstitution spikes and 2 needles |
| Rifampicin | Syrup 100 mg per 5 mL, 60 mL |
| Risedronic Acid and Calcium | Pack containing 4 tablets risedronate sodium 35 mg and 24 tablets calcium 500 mg (as carbonate) |
| Pack containing 4 enteric coated tablets risedronate sodium 35 mg and 24 tablets calcium 500 mg (as carbonate) | |
| Risedronic acid and calcium with colecalciferol | Pack containing 4 enteric coated tablets risedronate sodium 35 mg and 24 sachets containing granules of calcium carbonate 2.5 g with colecalciferol 22 micrograms |
| Risperidone | Oral solution 1 mg per mL, 100 mL |
| Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30 Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30 |
| Salmeterol | Powder for oral inhalation in breath actuated device 50 micrograms (as xinafoate) per dose, 60 doses |
| Silver sulfadiazine | Cream 10 mg per g, 50 g |
| Sirolimus | Oral solution 1 mg per mL, 60 mL |
| Sterculia with Frangula Bark | Granules 620 mg‑80 mg per g, 500 g |
| Tafluprost | Eye drops 15 micrograms per mL, single dose units 0.3 mL, 30 |
| Testosterone | Transdermal cream 50 mg per mL, 50 mL Transdermal gel 50 mg in 5 g sachet, 30 Transdermal gel (pump pack) 12.5 mg per 1.25 g dose, 60 doses, 2 Transdermal patches 12.2 mg, 60 Transdermal patches 24.3 mg, 30 Transdermal solution (pump pack) 30 mg per 1.5 mL dose, 60 doses |
| Theophylline | Oral solution 133.3 mg per 25 mL, 500 mL |
| Timolol | Eye gel 1 mg (as maleate) per g, 5 g |
| Eye drops 5 mg (as maleate) per mL, 5 mL | |
| Eye drops (gellan gum solution) 2.5 mg (as maleate) per mL, 2.5 mL | |
| Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL | |
| Tiotropium with olodaterol | Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses |
| Tobramycin | Eye drops 3 mg per mL, 5 mL Eye ointment 3 mg per g, 3.5 g |
| Tiotropium | Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations) |
| Tramadol | Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL |
| Travoprost | Eye drops 40 micrograms per mL, 2.5 mL |
| Travoprost with Timolol | Eye drops 40 micrograms travoprost with timolol 5 mg (as maleate) per mL, 2.5 mL |
| Triamcinolone with Neomycin, Gramicidin and Nystatin | Ear drops containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 7.5 mL Ear ointment containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 5 g |
| Trimethoprim with Sulfamethoxazole | Paediatric oral suspension 40 mg‑200 mg per 5 mL, 100 mL |
| Umeclidinium | Powder for oral inhalation in breath actuated device 62.5 micrograms (as bromide) per dose, 30 doses |
| Umeclidinium with vilanterol | Powder for oral inhalation in breath actuated device containing umeclidinium 62.5 micrograms (as bromide) with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses |
| Varenicline | Box containing 11 tablets 0.5 mg (as tartrate) and 14 tablets 1 mg (as tartrate) in the first pack and 28 tablets 1 mg (as tartrate) in the second pack |
| SCHEDULE 5—LIST OF STANDARD FORMULA PREPARATIONS | ||
| Form of pharmaceutical benefit | Standard formula preparations | |
| Creams | Salicylic Acid and Sulfur Aqueous APF | |
| Dusting Powders | Zinc, Starch and Talc APF 15 Zinc, Starch and Talc BPC 1973 | |
| Ear Drops | Aluminium Acetate APF | |
| Aluminium Acetate BP | ||
| Sodium Bicarbonate APF | ||
| Sodium Bicarbonate BP | ||
| Spirit APF | ||
| Eye Drops containing Cocaine Hydrochloride BP | — | |
| Eye Drops, Other | — | |
| Eye Lotions | — | |
| Inhalations | Benzoin and Menthol APF Menthol APF Menthol and Eucalyptus BP 1980 | |
| Linctuses containing Codeine Phosphate | Codeine APF | |
| Linctuses, Other | — | |
| Lotions | Aluminium Acetate Aqueous APF | |
| Mixtures containing Codeine Phosphate | — | |
| Mixtures, Other | Gentian Alkaline APF | |
| Kaolin BPC 1968 | ||
| Kaolin and Opium APF 14 | ||
| Magnesium Trisilicate BPC 1968 | ||
| Magnesium Trisilicate and Belladonna BPC 1968 | ||
| Mixtures for Children containing Codeine Phosphate BP | — | |
| Mixtures for Children, Other | — | |
| Mouth Washes | Thymol Compound APF 15 | |
| Nasal Instillations | — | |
| Ointments, Waxes | Benzoic Acid Compound APF | |
| Benzoic Acid Compound (extemporaneous formula) BP | ||
| Boric Acid, Olive Oil and Zinc Oxide QHF | ||
| Salicylic Acid APF | ||
| Salicylic Acid (extemporaneous formula) BP | ||
| Paints | Podophyllin Compound APF 16 Podophyllin Compound BP Salicylic Acid APF | |
| Pastes containing Cocaine Hydrochloride | — | |
| Pastes, Other | Zinc APF Zinc Compound (extemporaneous formula) BP | |
| Powders for Internal Use | Magnesium Trisilicate BP | |
| Solutions | — | |
Endnotes
Endnote 1—About the endnotes
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Editorial changes
The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.
If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.
If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.
Endnote 2—Abbreviation key
| ad = added or inserted | o = order(s) |
| am = amended | Ord = Ordinance |
| amdt = amendment | orig = original |
| c = clause(s) | par = paragraph(s)/subparagraph(s) |
| C[x] = Compilation No. x | /sub‑subparagraph(s) |
| Ch = Chapter(s) | pres = present |
| def = definition(s) | prev = previous |
| Dict = Dictionary | (prev…) = previously |
| disallowed = disallowed by Parliament | Pt = Part(s) |
| Div = Division(s) | r = regulation(s)/rule(s) |
| ed = editorial change | reloc = relocated |
| exp = expires/expired or ceases/ceased to have | renum = renumbered |
| effect | rep = repealed |
| F = Federal Register of Legislation | rs = repealed and substituted |
| gaz = gazette | s = section(s)/subsection(s) |
| LA = Legislation Act 2003 | Sch = Schedule(s) |
| LIA = Legislative Instruments Act 2003 | Sdiv = Subdivision(s) |
| (md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
| effect | SR = Statutory Rules |
| (md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
| cannot be given effect | SubPt = Subpart(s) |
| mod = modified/modification | underlining = whole or part not |
| No. = Number(s) | commenced or to be commenced |
Endnote 3—Legislation history
| Name | Registration | Commencement | Application, saving and transitional provisions |
| PB 119 of 2008 | 28 Nov 2008 (F2008L02618) | 1 Dec 2008 | |
| PB 131 of 2008 | 11 Dec 2008 (F2008L04645) | 1 Jan 2009 | — |
| PB 26 of 2009 | 18 Mar 2009 (F2009L01117) | 1 Apr 2009 | — |
| PB 38 of 2009 | 15 Apr 2009 (F2009L01321) | 1 May 2009 | — |
| PB 42 of 2009 | 11 May 2009 (F2009L01714) | 1 June 2009 | — |
| PB 53 of 2009 | 11 June 2009 (F2009L02293) | 1 July 2009 | — |
| PB 68 of 2009 | 10 July 2009 (F2009L02717) | 1 Aug 2009 | — |
| PB 81 of 2009 | 17 Aug 2009 (F2009L03153) | 1 Sept 2009 | — |
| PB 112 of 2009 | 20 Nov 2009 (F2009L04263) | 1 Dec 2009 | — |
| PB 122 of 2009 | 10 Dec 2009 (F2009L04556) | 1 Jan 2010 | — |
| PB 131 of 2009 | 13 Jan 2010 (F2010L00104) | 1 Feb 2010 | — |
| PB 20 of 2010 | 17 Mar 2010 (F2010L00678) | 1 Apr 2010 | — |
| as amended by | |||
| PB 32 of 2010 | 30 Mar 2010 (F2010L00775) | 31 Mar 2010 | — |
| PB 39 of 2010 | 15 Apr 2010 (F2010L00941) | 1 May 2010 | — |
| PB 48 of 2010 | 21 May 2010 (F2010L01379) | 1 June 2010 | — |
| PB 58 of 2010 | 21 June 2010 (F2010L01622) | 1 July 2010 | — |
| PB 73 of 2010 | 19 July 2010 (F2010L02067) | 1 Aug 2010 | — |
| PB 99 of 2010 | 29 Oct 2010 (F2010L02858) | 1 Nov 2010 | — |
| PB 111 of 2010 | 30 Nov 2010 (F2010L03128) | 1 Dec 2010 | — |
| PB 121 of 2010 | 17 Dec 2010 (F2010L03306) | 1 Jan 2011 | — |
| PB 8 of 2011 | 28 Jan 2011 (F2011L00164) | 1 Feb 2011 | — |
| PB 26 of 2011 | 28 Mar 2011 (F2011L00509) | 1 Apr 2011 | — |
| PB 37 of 2011 | 26 May 2011 (F2011L00867) | 1 June 2011 | — |
| PB 52 of 2011 | 27 July 2011 (F2011L01544) | 1 Aug 2011 | — |
| PB 59 of 2011 | 29 Aug 2011 (F2011L01764) | 1 Sept 2011 | — |
| PB 68 of 2011 | 28 Sept 2011 (F2011L01986) | 1 Oct 2011 | — |
| PB 85 of 2011 | 28 Nov 2011 (F2011L02475) | 1 Dec 2011 | — |
| PB 97 of 2011 | 19 Dec 2011 (F2011L02736) | 1 Jan 2012 | — |
| PB 15 of 2012 | 29 Mar 2012 (F2011L00715) | 1 Apr 2012 | — |
| PB 29 of 2012 | 26 Apr 2012 (F2012L00937) | 1 May 2012 | — |
| PB 34 of 2012 | 8 May 2012 (F2012L01004) | 1 June 2012 | — |
| PB 38 of 2012 | 15 June 2012 (F2012L01202) | 1 July 2012 | — |
| PB 46 of 2012 | 25 July 2012 (F2012L01601) | 1 Aug 2012 | — |
| PB 63 of 2012 | 22 Aug 2012 (F2012L01732) | 1 Sept 2012 | — |
| PB 75 of 2012 | 28 Sept 2012 (F2012L01969) | 1 Oct 2012 | — |
| PB 95 of 2012 | 29 Nov 2012 (F2012L02287) | 1 Dec 2012 | — |
| PB 5 of 2013 | 21 Jan 2013 (F2013L00071) | 22 Jan 2013 (s 2) | — |
| PB 9 of 2013 | 14 Feb 2013 (F2013L00186) | 1 Mar 2013 (s 2) | — |
| PB 33 of 2013 | 24 May 2013 (F2013L00840) | 1 June 2013 (s 2) | — |
| PB 49 of 2013 | 29 July 2013 (F2013L01459 | 1 Aug 2013 (s 2) | — |
| PB 59 of 2013 | 15 Aug 2013 (F2013L01578) | 1 Sept 2013 (s 2) | — |
| PB 80 of 2013 | 29 Nov 2013 (F2013L02015) | 1 Dec 2013 (s 2) | — |
| PB 91 of 2013 | 20 Dec 2013 (F2013L02167) | 1 Jan 2014 (s 2) | — |
| PB 3 of 2014 | 10 Jan 2014 (F2014L00050) | 1 Feb 2014 (s 2) | — |
| PB 10 of 2014 | 14 Feb 2014 (F2014L00144) | 1 Mar 2014 (s 2) | — |
| PB 19 of 2014 | 27 Mar 2014 (F2014L00357) | 1 Apr 2014 (s 2) | — |
| PB 29 of 2014 | 11 Apr 2014 (F2014L00401) | 1 May 2014 (s 2) | — |
| PB 38 of 2014 | 22 May 2014 (F2014L00593) | 1 June 2014 (s 2) | — |
| PB 46 of 2014 | 19 June 2014 (F2014L00761) | 1 July 2014 (s 2) | — |
| PB 57 of 2014 | 30 July 2014 (F2014L01052 ) | 1 Aug 2014 (s 2) | — |
| PB 62 of 2014 | 25 Aug 2014 (F2014L01125) | 1 Sept 2014 (s 2) | — |
| PB 74 of 2014 | 26 Sept 2014 (F2014L01256) | 1 Oct 2014 (s 2) | — |
| PB 83 of 2014 | 23 Oct 2014 (F2014L01393) | 1 Nov 2014 (s 2) | — |
| PB 90 of 2014 | 28 Nov 2014 (F2014L01599) | 1 Dec 2014 (s 2) | — |
| PB 108 of 2014 | 22 Dec 2014 (F2014L01772) | 1 Jan 2015 (s 2) | — |
| PB 2 of 2015 | 14 Jan 2015 (F2015L00039) | 1 Feb 2015 (s 2) | — |
| PB 12 of 2015 | 25 Feb 2015 (F2015L00207) | 1 Mar 2015 (s 2) | — |
| PB 28 of 2015 | 26 Mar 2015 (F2015L00338) | 1 Apr 2015 (s 2) | — |
| PB 41 of 2015 | 24 Apr 2015 (F2015L00589) | 1 May 2015 (s 2) | — |
| PB 49 of 2015 | 29 May 2015 (F2015L00764) | 1 June 2015 (s 2) | — |
| PB 56 of 2015 | 1 July 2015 (F2015L01065) | 1 July 2015 (s 2) | — |
| PB 70 of 2015 | 31 July 2015 (F2015L01205) | 1 Aug 2015 (s 2) | — |
| PB 80 of 2015 | 28 Aug 2015 (F2015L01350) | 1 Sept 2015 (s 2) | — |
| PB 92 of 2015 | 30 Sept 2015 (F2015L01539) | 1 Oct 2015 (s 2) | — |
| PB 109 of 2015 | 1 Dec 2015 (F2015L01894) | 1 Dec 2015 (s 2) | — |
| PB 119 of 2015 | 24 Dec 2015 (F2015L02139) | 1 Jan 2016 (s 2) | — |
| PB 3 of 2016 | 1 Feb 2016 (F2016L00077) | 1 Feb 2016 (s 2) | — |
| PB 20 of 2016 | 1 Apr 2016 (F2016L00469) | 1 Apr 2016 (s 2) | — |
| PB 31 of 2016 | 29 Apr 2016 (F2016L00603) | 1 May 2016 (s 2) | — |
| PB 44 of 2016 | 30 May 2016 (F2016L00855) | 1 June 2016 (s 2) | — |
| PB 53 of 2016 | 22 June 2016 (F2016L01058) | 1 July 2016 (s 2) | — |
| PB 65 of 2016 | 19 July 2016 (F2016L01196) | 1 Aug 2016 (s 2) | — |
| PB 74 of 2016 | 18 Aug 2016 (F2016L01298) | 1 Sept 2016 (s 2) | — |
| PB 108 of 2016 | 30 Nov 2016 (F2016L01835) | 1 Dec 2016 (s 2) | — |
Endnote 4—Amendment history
| Provision affected | How affected |
| s 1.......................................... | rep LA s 48D |
| s 2.......................................... | rep LA s 48C |
| s 3.......................................... | am PB 59 of 2011; PB 75 of 2012 |
| s 5.......................................... | am PB 75 of 2012 |
| s 6.......................................... | am PB 75 of 2012 |
| s 9.......................................... | am PB 59 of 2011; PB 75 of 2012 |
| Schedule 1 | |
| Schedule 1.............................. | am PB 68 of 2009; PB 37 and 59 of 2011; PB 46 of 2012; PB 70 of 2015 |
| Schedule 3 | |
| Schedule 3.............................. | am PB 26, 38 and 131 of 2009; PB 52, 59 and 85 of 2011; PB 38 of 2012; PB 5 of 2013; PB 3, 19 and 38 of 2014; PB 80 of 2015; PB 3, 20, 31, 44, 65 and 74 of 2016 |
| Schedule 4 | |
| Schedule 4.............................. | am PB 131 of 2008; PB 26, 42, 53, 68, 81, 112, 122 and 131 of 2009; PB 20 of 2010 (as am by PB 32 of 2010); PB 39, 48, 58, 73, 99, 111 and 121 of 2010; PB 8, 26, 37, 59, 68 and 97 of 2011; PB 15, 29, 34, 38, 46, 63, 75 and 95 of 2012; PB 9, 33, 49, 59, 80 and 91 of 2013; PB 10, 19, 29, 38, 46, 57, 62, 74, 83, 90 and 108 of 2014; PB 2, 12, 28, 41, 49, 56, 70, 80, 92, 109 and 119 of 2015; PB 20 (Sch 1 item 3 md), 31, 53, 65 and 108 of 2016 |
0
0
0